Michael Baldwin

TL;DR: All LAMA/LABA FDCs were found to have similar efficacy and safety, and Definitive assessment of the relative efficacy of different treatments can only be performed through direct comparison in head-to-head RCTs.

TL;DR: A unique patient-level simulation model is developed that can be used to evaluate COPD treatment options for a variety of subgroups and results for a selection of treatment scenarios and subgroups were shown to demonstrate the potential of the model.

TL;DR: Tiotropium + olodaterol Respimat® FDC is a cost-effective bronchodilator in the maintenance treatment of COPD for the Italian health care system using a newly developed patient-level Markov model that reflects the current understanding of the disease.

TL;DR: The strongest drivers of preference in French users of inhalation devices for COPD are shape, dose counter and reusability, which are important to patients and should be taken into account by clinicians prescribing these devices.

TL;DR: Almost all patients endorsed the symptoms assessed by the L-PF: shortness of breath, cough, cough and fatigue; most patients endorsed impacts of progressive fibrosing ILD on activities of daily living, physical well-being, sleep, emotional well- Being, and social aspects of their lives.